EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (NasdaqGM: ADLR) today reported net product sales of ENTEREG® (alvimopan) for the three and six months ended June 30, 2009 of approximately $2.4 million and $3.8 million, respectively, on total net shipments of approximately $2.9 million and $4.9 million, respectively. Under Adolor’s current revenue recognition policy, revenue related to a customer shipment is deferred until subsequent re-orders by that customer. As of June 30, 2009, there were approximately 450 repeat-order hospitals for ENTEREG, up from 300 at March 31, 2009.
